Objective: To evaluate tumor growth in a series of patients undergoing liver resection after portal vein embolization (PVE). Background: The regenerative response after PVE leading to compensatory hypertrophy of the nonembolized liver segments potentially enhances tumor growth. Methods: Portal vein embolization was performed in 28 patients diagnosed with colorectal metastases between 2004 and 2011. Tumor volume was measured by computed tomography (CT) volumetry before and after PVE. Tumor growth rate (TGR) was measured by CT volumetry and compared with that of a non-PVE control group with colorectal metastases of whom 30 had 2 CT scans preoperatively. Also, newly diagnosed tumors in the future remnant liver (FRL) after PVE and after resection were analyzed. Results: The median TGR of PVE patients was 0.53 mL/d (interquartile range [IQR], 0.02-1.88) versus 0.09 mL/d (IQR, −0.04 to 0.40; P = 0.03) in non-PVE patients. The TGR was 0.15 (IQR, −0.52 to 0.66) mL/d before PVE and 0.85 (IQR, −0.10 to 1.62) mL/d after PVE in the same patients (P = 0.03). Seven patients (25%) showed new tumor lesions in the FRL after PVE, of whom 3 patients (11%) were not resectable. Patients (8 of 19; 42%) after PVE also showed a higher rate of recurrent metastases in the remnant liver at follow-up than non-PVE patients (1 of 28; 4%). Survival was significantly better for non-PVE patients, with a 3-year survival rate of 77% versus 26% in patients undergoing PVE. Conclusions: Portal vein embolization is associated with increased TGR and new tumor in the FRL and recurrent tumor after resection. Short intervals and interval chemotherapy between PVE and resection are, therefore, advised.
T he only curative treatment for malignant liver tumors is (partial) liver resection. Not all tumors are resectable, in many cases because the future remnant liver (FRL) is too small with a high risk of postoperative liver failure, which is the major cause of mortality after extended liver resections and especially in patients with compromised liver, such as cirrhosis, steatosis, cholestasis, fibrosis, or after extensive chemotherapy. 1 Portal vein embolization (PVE) 2,3 is an accepted method worldwide to increase the resectability rate of patients with liver tumors by inducing hypertrophy of the nonembolized FRL. Several studies describe the possibility of enhanced tumor growth after PVE [4] [5] [6] [7] [8] [9] as a result of cytokines, growth factors, and an increased arterial blood supply, but the exact mechanisms of this phenomenon are still unknown. Growth of tumor may be accelerated, whereas micrometastases in the nonembolized remnant liver may also develop or progress. The potential boost of tumor proliferation, therefore, cre-ates a dilemma in terms of optimal waiting time until resection. The aim of this study was to examine the consequences of preoperative PVE for tumor growth in a series of patients prepared for resection in our department.
METHODS

Study Characteristics
The results of patients with colorectal metastases (CRM) of the liver (n = 28) undergoing preoperative PVE (PVE group) from 2004 to 2011 were compared with those of a series of patients with CRM (n = 30) who underwent liver resection without PVE (non-PVE group), in whom 2 sequential CT scans were performed before liver resection. The median follow-up was 6 (interquartile range [IQR], 0-27) months in the PVE group and 40 (IQR, 26-52) months in the non-PVE group.
Management Policy
The standard diagnostic workup included a multiphase CT scan, magnetic resonance imaging, or dynamic ultrasound of the liver as required. A multidisciplinary team evaluated the imaging studies and came up with a proposal for treatment of patients with CRM. Of all PVE patients, CT scans were performed in the portal phase. The total liver volume (TLV), tumor volume (TV) in the embolized liver lobe, and the future remnant liver volume (FRLV) were determined by CT volumetry in the pre-PVE and post-PVE scans. The percentage of the FRL was calculated according to the following formula: FRLV × 100/(TLV − TV). Tumor progression was also recorded if presenting in the FRL after PVE. Twenty-eight patients with CRM were examined in the PVE group. In all PVE patients, CT scans were made before PVE and 3 weeks later. However, 2 sequential scans were performed before PVE in 10 patients. These scans were made to assess tumor response to chemotherapy or to check for new, extrahepatic disease during therapy. Another reason for an extra CT scan was to perform the CT-volumetry calculations, which can be determined only on our own workstation, indicating that scanning techniques and images were comparable. In these patients, TVs and growth could be determined before PVE in the same patient group. Follow-up CT scans were made after liver resection to detect recurrent tumor.
In 30 patients of the non-PVE group, CT volumetric data (TLV, TV, and FRLV) were assessed in 2 sequential CT scans performed before liver resection. First, the volumes were determined, after which the calculations were performed. The results of the volumes measured by CT volumetry were determined by 2 independent, experienced investigators, showing no major variations and resulting in reproducible assessments. Calculations were made using established formulas.
To assess TV changes, tumor volumes were determined and the linear tumor growth rate (TGR) per day was calculated by using the following formulas:
• For PVE patients: (TV after PVE − TV before PVE )/number of days between scans before surgery if only 1 scan was performed before PVE, and (TV second scan before PVE − TV first scan before PVE )/number of days between scans before PVE for patients in whom 2 sequential scans were performed before PVE (n = 10). • For non-PVE patients: (TV second scan before surgery − TV first scan before surgery )/number of days between scans before surgery .
Although the earlier-mentioned formulas to calculate TGR implies a linear growth, tumor growth of CRM is likely exponential. Therefore, we also calculated the exponential TGR (ETGR) for characterization of an exponentially growing tumor, by using the following formula: ETGR = ln(TV 2 /TV 1 )/(t 2 − t 1 ), in which TV = tumor volume and t = time, described as the "specific growth rate" by Mehrara. 10 New tumor lesions were also reported in the FRL after resection. Follow-up time was recorded as the period between resection date and the last date of follow-up. Survival was analyzed according to the date of liver resection until the date of death.
Chemotherapy
The administered chemotherapy regimens (the number of cycles) varied among patients and groups. In most patients, the combination of oxaliplatin and/or capecitabine with or without bevacizumab was given. Some patients received capecitabine, irinotecan, panitumumab, or oxaliplatin with 5-fluorouracil/leucovorin. In view of the large variation, we took into account only the mere fact whether patients received chemotherapy or not.
Statistical Analysis
The data were analyzed by statistical software (SPSS for Windows 18.0; SPSS, Chicago, IL) and GraphPad Prism (Graph-Pad Software, San Diego, CA). The nonparametric Mann-Whitney U test was used for comparing unpaired data that were not normally distributed between the PVE group and the non-PVE group. For parametric, paired data, the paired t test was used. Normally distributed data were described as mean ± SEM. The Wilcoxon signed rank test was used for comparisons of paired data that were not normally distributed, between pre-PVE and post-PVE in the patients undergoing PVE (n = 10). The χ 2 test was used for comparing binary data across the PVE group and the non-PVE group (unpaired). The Spearman correlation coefficient was calculated for the correlation between TGR or TV increase and increased FRL and between the number of cycles of chemotherapy and TGR or tumor-size changes. Survival curves were generated by the Kaplan-Meier method. A P value more than 0.05 was considered statistically significant.
RESULTS
Portal vein embolization was successfully performed in all patients of the present series, without PVE-related complications. After PVE, liver resection was carried out in the majority of patients. Characteristics of patients with and without PVE are shown in Table 1 .
Tumor Volume
In 28 PVE patients, a mean TV of 131.4 ± 44.3 mL before PVE versus 180.0 ± 55.2 mL after PVE was seen after an overall time interval of 51.4 ± 5.4 days (P = 0.011). In this group, an increase in TV after PVE was found in 23 patients, of whom 13 patients (57%) had received chemotherapy before PVE, whereas 5 patients showed a decrease in tumor size after embolization, of whom 4 patients (80%) were administered chemotherapy. There was a time interval of 29.1 ± 5.4 days between the first CT scan and the PVE compared with 22.2 ± 0.7 days between PVE and the second scan (3 weeks after PVE). In a subgroup of 10 patients, 2 sequential CT scans were made before PVE, with a time interval of 44.2 ± 12.1 days between scans. These patients showed a stable TV from 176.3 ± 87.3 mL to 179.4 ± 87.2 mL (P = 0.758) before PVE.
In the non-PVE group (n = 30), a mean TV of 153.2 ± 54.9 mL was seen on the first scan versus 118.2 ± 36.5 mL on the second scan. An increase in TV was found in 19 patients (63%), with a mean time interval of 107.85 ± 19.15 days between the 2 scans performed before liver resection for all patients (n = 30). The decrease in tumor size in 11 patients is probably related to the use of chemotherapy. In patients who received chemotherapy preoperatively in the non-PVE group (n = 14), a decrease in TV was seen from 267.5 ± 108.8 mL to 158.7 ± 68.1 mL (P = 0.245). Conversely, patients who had no chemotherapy in the non-PVE group (n = 16) showed an increase in TV between the initial and second scans (from 53.3 ± 22.9 mL to 82.7 ± 33.8 mL), although not significantly different (P = 0.099).
Tumor Growth Rate
The TGR of the patients (n = 28) who underwent PVE was significantly greater before surgery than that of the non-PVE patients, showing median TGR of 0.53 (IQR, 0.02-1.88) mL/d and 0.09 (IQR, −0.04 to 0.40) mL/d, respectively (P = 0.03). No significant differences were seen in patients in whom chemotherapy was administered preoperatively ( Table 1) .
The median TGR in the 10 PVE patients in whom 2 scans were performed before PVE was 0.15 (IQR, −0.52 to 0.66) mL/d, which increased to 0.85 (IQR, −0.10 to 1.62) mL/d after PVE in the same patients (P = 0.03). Figure 1 summarizes the results of TGR. 
Exponential Tumor Growth Rate
In the PVE patients, a median ETGR of 0.0061 (IQR, 0.0023-0.0244) ln(ml)/d was found, compared with a median of 0.0040 (IQR, −0.0039 to 0.0099) ln(ml)/d in the non-PVE group (P = 0.269). In the patients undergoing PVE (n = 10), the median ETGR was 0.0004 (IQR, −0.0073 to 0.0143) ln(ml)/d before PVE, and 0.0054 (IQR, −0.0090 to 0.0186) ln(ml)/d after PVE, showing enhanced tumor proliferation after PVE compared with pre-PVE (P = 0.139). These results did not reach statistical significance but are numerically in line with the outcomes of the linear TGRs, showing tumor progression after PVE.
Future Remnant Liver
The PVE group (n = 28) showed a significant increase in the FRL volume after PVE. The mean FRL volume pre-PVE was 480.7 ± 31.9 mL versus 716.1 ± 48.7 mL post-PVE (P < 0.001), which corresponds with a 28.5% FRL before PVE and 42.1% after PVE. No significant correlations between TV increase and increased FRL were found (ρ = 0.423).
Seven of 28 PVE patients (25%) showed new tumor lesions in the FRL 3 weeks after PVE. Three of these patients (11%) were not deemed resectable after PVE for this reason. When examining the first follow-up imaging after resection, PVE patients showed a higher proportion (8 of 19; 42%) of recurrent metastases in the remnant liver than the non-PVE patients (1 of 28; 4%). The median time interval between the resection and the first follow-up imaging was 82 (range, 6-297) days in the PVE group and 102 (range, 5-762) days in the non-PVE group (P = 0.011).
Chemotherapy
Chemotherapy before PVE was administered in 17 of 28 patients (61%), of whom 1 patient also received chemotherapy after PVE, before resection. Another patient received chemotherapy only in the time period between PVE and surgery (3 cycles). No significant correlations were found between the changes in TV after PVE in patients who received chemotherapy or not preceding PVE (r = 0.262, P = 0.178). Also, no significant correlations were found between TGR and the number of cycles of chemotherapy (ρ = −0.075, P = 0.703). In the non-PVE group (n = 30), 14 patients received chemotherapy before surgery. Again, no significant correlations were seen between tumor-size changes or TGR and (cycles of) chemotherapy (ρ = −0.081, P = 0.782, and ρ = −0.024, P = 0.935, respectively).
Survival
We demonstrate a 3-year survival rate of 26% in our series of PVE patients (Fig. 2) . These patients would otherwise not have been resected on the basis of the initial results of CT volumetry. The 3 patients with CRM (11%) who proved unresectable after PVE survived 5, 10, and 20 months, respectively, while palliative chemotherapy was administered. These patients were considered unresectable because of disease progression. Survival was better for non-PVE patients with a 3-year survival rate of 77% versus 26% in patients undergoing PVE.
DISCUSSION
A schematic overview of the literature results pertinent to PVE and tumor growth is shown in Table 2 . The literature review suggests that PVE potentially induces tumor proliferation after PVE, but there are no solid data to corroborate this notion. An important point is the natural history of tumor growth over time. It has been reported that the mean doubling time of CRM found by the surgeon at laparotomy is 155 ± 34 days, in comparison with 86 ± 12 days for CRM detected by the CT scan postoperatively. 11 We assessed the outcomes of PVE in our department, using a large sample size, with the main focus on TV and growth changes after PVE. Furthermore, we paid special attention to potential tumor development in the FRL after PVE and the effects of chemotherapy. We showed a significant increase in mean TV after PVE, although this increase cannot be ascribed to PVE alone. A control group was, therefore, included in this study to compare the outcomes with patients who did not undergo PVE. This is the first study to compare patients with and without PVE in whom tumor growth before and after PVE is reported, allowing us to compare clinical tumor progression before and after PVE.
The time intervals between the scans were different within and between groups; therefore, we calculated the TGR and ETGR per day, which are better indicators of tumor proliferation. We found a higher TGR after PVE than before PVE (0.85 vs 0.15 mL/d) in the same patients in our series, which is consistent with the results of Hayashi et al. 6 Furthermore, our results show that PVE is associated with larger TGR in comparison with patients who do not require preoperative PVE; a similar finding was found in the study of Pamecha et al. 9 The effects of PVE on tumor progression are not always clinically relevant because the tumor is commonly located in the part of the liver that will be resected. However, when the tumor is located near the intended resection plane or liver hilum, an increase of tumor volume may become troublesome. Besides, if PVE also increases tumorigenesis, new tumors may develop in the FRL, endangering resectability of the patient. We assume that PVE can lead to the activation of dormant micrometastases in the FRL, whereas the presence of microtumors is not detectable by imaging studies before PVE or liver resection. These micrometastases are stimulated to grow by the process of liver regeneration triggered by PVE, comprising both cytokines and growth factors. It remains uncertain whether new tumors in the remnant liver are true new tumors or microtumors that were present but not detectable by imaging studies before PVE. Either way, PVE does provide a biological test to identify undetectable lesions before undertaking resection, which otherwise would obviously become apparent in the follow-up after resection (under the influence of postresectional regeneration). In this regard, these new findings are helpful as they may prevent a futile liver resection. In literature, survival outcomes of patients resected after PVE compared with those of non-PVE patients have been reported. In the study of Wicherts et al, 12 non-PVE patients had a significantly better survival rate than PVE patients, with a 3-year survival rate of 61% and 44%, respectively, outcomes that compare reasonably well with the 3-year survival rates reported in our series, that is, 77% and 26%, respectively. Remarkably, of the 99 patients who received PVE in the study by Wicherts et al, 12 32 patients (32%) were not resectable after PVE because the tumor had spread (n = 27) or an insufficient hypertrophy response had occurred. Of the latter patients, 10 patients survived for 1 year, 8 patients died within 2 years and, finally, no patients survived longer than 3 years after PVE. In our study, only 3 patients (10.7%) were not able to undergo resection after PVE, and these patients showed a survival of 10.3 ± 8.4 (range, 5-20) months.
One of the remaining questions is whether there are other reasons why survival outcomes should be different between patients who underwent PVE and those who did not. Survival could be influenced by chemotherapy, the size of the biggest lesion, the number of lesions, and synchronous or metachronous tumors (Table 1) . Ideally, independent predictors of poor long-term outcomes are determined by multivariate analysis; however, this was not possible in our study comprising 58 patients in total.
Our study has some limitations. First, a PVE group was compared with a non-PVE group, although the tumor burden in patients requiring PVE is usually higher and its prognosis worse, leading to a bias in selection. Furthermore, the volumes of liver metastases were different between both groups at presentation (ie, non-PVE: 153.3 ± 54.9, PVE: 131.4 ± 44.3), although not statistically significant (P = 0.472). However, this is the first report of a series with a large sample Many patients undergo both PVE and chemotherapy. The latter, because of its antiproliferative effect, may hamper regeneration and influence postoperative complications. In most patients of this study, chemotherapy was administered before PVE. Some studies showed excellent results of the combination of chemotherapy and PVE in relation to the liver hypertrophy response after PVE. [13] [14] [15] Chemotherapy pre-PVE did not impair liver regeneration in response to PVE. Also, survival and morbidity and mortality rates were similar for patients undergoing a 2-stage hepatectomy (chemotherapy first, then minor hepatectomy, followed by portal vein ligation or PVE if indicated, and finally major hepatectomy) compared with those undergoing a single-stage hepatectomy. 14 Several studies favor stopping chemoembolization 6 to 8 weeks before any intervention, such as PVE or liver resection. 15, 16 The key questions are whether chemotherapy administered post-PVE inhibits tumor progression and which time interval should be observed between cessation of chemotherapy and resection after PVE. These are important issues to be studied in future research. Recently, de Graaf et al 17 compared the increase in the FRL function after PVE as measured by dynamic 99mTc-mebrofenin hepatobiliary scintigraphy, with the increase in the FRL volume as measured by CT volumetry. They showed that 23 ± 4.9 days after PVE, the increase in the FRL function exceeded the increase in the FRL volume. These findings suggest that the recommended waiting time until operation may be shorter than usually indicated by volumetric parameters. Therefore, we assume that a waiting time of 2 to 3 weeks is sufficient between PVE and resection. Furthermore, there seems to be a place for chemotherapy in the waiting time after PVE to control tumor growth. Goere et al 18 compared 10 patients treated by chemotherapy in the interval between PVE and hepatectomy with 10 patients without chemotherapy. They reported that chemotherapy can be safely continued until liver surgery when the portal vein is embolized without impairment of the hypertrophy of the future remnant volume or the postoperative course after liver resection. In contrast, Beal et al 19 showed that chemotherapy administered in the interval between PVE and liver resection impaired liver hypertrophy. However, Beal et al 19 observed that patients without chemotherapy were more likely to have tumor progression between embolization and liver resection. Concluding from their study, the authors demonstrated that chemotherapy between PVE and hepatectomy did not prevent but did reduce liver hypertrophy after PVE. 19 Transarterial chemoembolization has also been used to prevent tumor progression. 20 The combination of transarterial chemoembolization and PVE has a strong anticancer effect, 21 and, therefore, has a strong potential to suppress tumor growth after PVE.
Although our results support the evidence from literature that PVE increases tumor growth, further research is required to confirm these findings. Ideally, in a clinical trial, patients would be randomized to undergo liver resection for similar tumor burden to receive preoperative PVE or not. Only 1 prospective clinical trial has been published in which patients were randomized to undergo PVE or not. 22 The authors concluded that in patients with normal livers, there was no benefit of liver regeneration induced by PVE on postoperative outcomes. A criticism of the latter study design is that only standard right hepatectomies were performed, leaving out the extended rightliver resections, which are the resections prone to insufficient FRL. A randomized controlled trial is unethical to perform, in our opinion, because most patients who require preoperative PVE are unresectable without PVE.
CONCLUSIONS
There is evidence that PVE increases tumor growth in both the embolized and nonembolized sides of the liver. The beneficial effects of preoperative PVE on the FRL volume must, therefore, be weighed against potential enhancement of tumor growth in the tumorbearing lobe and induction of new tumor in the FRL after PVE or recurrent tumor after PVE and resection. We, therefore, advise short intervals (ie, 2-3 weeks) between PVE and resection and interval chemotherapy. 23 I imagine that many of us actually share your concerns that attempts to increase the intended residual liver volume by portal vein embolization (PVE) may be counterproductive, and some have argued, as you have done, that there is a risk that tumor growth will be stimulated in this way. I do have some concerns though, when looking back retrospectively at a management approach and endeavoring to make sense of the outcome when the management policy is not perhaps available or often well defined--particularly in such a challenging group of patients with aggressive liver involvement by colorectal tumor. It is evident that the 2 groups are not entirely comparable because the PVE group, inevitably, has a greater tumor burden-so you would imagine that they might fare worse. So my first question concerns the initial staging and management of these patients. Did all the patients undergo positron emission tomography (PET) computed tomography (CT) before chemotherapy and conventional staging investigations?
You identified a number of chemotherapeutic regimens that would be employed in this patient population. Why was this variation there, and did all the patients actually complete the chemotherapy treatment schedules as planned? You have concluded that PVE increases tumor volume (TV) and tumor growth rate and induces new tumor in the future remnant liver, but if I understand the data correctly, I think about a quarter of the patients developed new lesions in the future remnant liver within 3 weeks of PVE. So are you suggesting that these are new lesions, which have developed after portal embolization, or are these occult lesions? If they are occult lesions, it could be argued that their eventual detection has avoided unnecessary resection in a patient population with advanced disease.
Finally, I wanted to focus on the solution that you are suggesting. You are indicating that perhaps the interval between PVE and resection be reduced and administration of interval chemotherapy between PVE and resection. Now is this really practical, how can you actually reduce this time from the existing 3 to 4 weeks without perhaps then running into problems with increased risk of liver failure in these patients? I enjoyed your presentation, but it seems that the study actually raises more questions than it answers.
Response From Dr Lisette Hoekstra (Amsterdam, The Netherlands)
Regarding your first comment in which you point out that the groups were not exactly comparable, I agree. I think it is very difficult to find a PVE group that you can compare with a control group, which is exactly the same. Indeed, the tumor burden in patients requiring PVE is usually higher and prognosis worse, leading to a bias in selection. However, in our study, the TVs at presentation were not significantly different between the groups. Besides that, it was a relatively large sample size, and we also looked at tumor growth before and after embolization, which is, in our opinion, a better marker of tumor proliferation. Of course, it would be ideal to conduct a prospective trial in which patients who undergo PVE are randomized and compared with patients who do not undergo PVE with comparable tumor burden. However, I think, it is difficult and unethical to perform such a study, because the patients who require PVE are otherwise not resectable.
Regarding your question concerning the staging investigation of our patients, the standard diagnostic workup included a multiphasic CT scan in all patients, which accurately detects colorectal liver metastasis as is advised by our radiologist. Positron emission tomography CT scan as a diagnostic imaging tool was routinely used as of 2008, resulting in 10 PET CT scans in the PVE group and 14 PET CT scans in the non-PVE group. Therefore, I cannot present these results because the data are not complete.
In answer to your question concerning the administered chemotherapy, we do not believe that chemotherapy influenced the (survival) outcomes, because no significant differences were seen between both groups in regard to treatment regimens of chemotherapy, as shown in Table 1 of the article. Hence, there was no variation in chemotherapy regimens between groups, and all patients completed their treatment schedules.
We indeed observed that 7 of 28 patients (25%) showed new tumor lesions in the FRL 3 weeks after PVE. We suggest that these lesions have newly developed, although it remains uncertain whether these are true new tumors or microtumors that were present already but were not detectable by imaging studies before PVE and were stimulated to grow by the process of liver regeneration.
Concerning your last question, there are 2 strategies to prevent tumor proliferation in the time between PVE and hepatectomy. The waiting time until resection can be decreased or chemotherapy can be applied in the period from PVE until resection. When using CT volumetry, the volume increase of the FRL after PVE usually plateaus after 3 weeks. Apart from CT volumetry, we use hepatobiliary scintigraphy with Tc-labeled mebrofenin to assess function of the FRL. We have previously reported (de Graaf et al 17 ) that the increase in the FRL function exceeds the increase in the FRL volume, suggesting that the recommended waiting time until operation may be shorter than usually indicated by volumetric parameters. Therefore, we assume that the interval between PVE and resection can be reduced to 2 to 3 weeks.
DISCUSSANTS
A.D. (Antonio) Pinna (Bologna, Italy):
I think the lesions that appear 3 weeks after embolization were probably already present in the liver. Magnetic resonance imaging (MRI) should be done first before proceeding with embolization. Do you think that after embolization there could be a difference in the density of the liver parenchyma, so you have actually a false-positive increase in the growth of the tumor after embolization? Do you think that we should avoid embolization when the metastasis is sitting in segment 4?
Response From Dr Lisette Hoekstra (Amsterdam, The Netherlands):
Regarding your first question, micro-metastases are too small to be detected by an MRI. Also, there is a controversy regarding whether you should perform an MRI or a CT scan for detection of liver metastases. However, we will continue this study, also including MRI in the standard diagnostic workup.
Regarding your second question, we have found no signs on CT indicating that there is a difference in the density of liver parenchyma adjacent to the tumor, which would possibly result in a false-positive increase of tumor growth.
In answer to your last question, controversy exists concerning embolization of the portal branches to segment 4 in preparation of extended right hemihepatectomy in addition to embolization of the right portal trunk, and, therefore, it is advised only in selected cases.
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